Biobeat Technologies Ltd: Valuation, Funding & Investors
Biobeat develops a patch-worn, cuff-less 24-hour ambulatory blood pressure monitoring (ABPM) system and is the first to receive FDA clearance for this technology. The company focuses on expanding clinical utilization and commercial adoption of ABPM to improve diagnosis and management of hypertension by providing continuous, high-quality blood pressure data integrated with electronic medical records.
Leadership & Board
- Current Number of Employees
- 77
- Current LinkedIn Followers
- 21,340
Latest Estimated Valuation
- Total Amount Raised
- $50M
- Total Funding Rounds
- 1
- Latest Funding Amount
- $50M
- Latest Funding Round
- Series B
Employee Trend
Biobeat Technologies Ltd had 77 employees as of November 2, 2026. The number of employees increased by 0 (0.00%) week-over-week.
Social Trend
Biobeat Technologies Ltd had 21,340 followers as of November 2, 2026. The number of followers increased by 44 (0.21%) week-over-week.
Main Enterprise Clients
A snapshot of major enterprise customers that use this private company’s products or services, highlighting its commercial reach and market adoption.
Funding Round
| Funding Date | Funding Round | Amount Raised | Post-Money Valuation |
|---|---|---|---|
| Dec 30, 2025 | Series B | $50.00M | ― |
Investors
| Investor Name | Funding Round |
|---|---|
| Orbimed Advisors | Series B |
| Ally Bridge Group | Series B |
| Elevage Medical | Series B |
Similar Companies
A snapshot of private companies similar to Biobeat Technologies Ltd, helping you discover and navigate related company profiles.
Related News and Analysis
